Wall Street brokerages expect Amedisys Inc (NASDAQ:AMED) to post $388.54 million in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Amedisys’ earnings, with the highest sales estimate coming in at $397.58 million and the lowest estimate coming in at $381.20 million. Amedisys reported sales of $361.60 million in the same quarter last year, which indicates a positive year-over-year growth rate of 7.5%. The company is scheduled to report its next earnings report on Thursday, November 2nd.

According to Zacks, analysts expect that Amedisys will report full-year sales of $388.54 million for the current financial year, with estimates ranging from $1.52 billion to $1.55 billion. For the next fiscal year, analysts expect that the business will post sales of $1.62 billion per share, with estimates ranging from $1.61 billion to $1.64 billion. Zacks’ sales averages are an average based on a survey of research firms that follow Amedisys.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million for the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. Amedisys’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the firm posted $0.42 EPS.

A number of analysts have recently weighed in on AMED shares. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $59.00 price objective for the company in a research report on Monday, April 17th. Jefferies Group LLC reissued a “buy” rating and issued a $57.00 price objective on shares of Amedisys in a research report on Friday, April 28th. Mizuho raised Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price objective for the company in a research report on Wednesday, May 3rd. BidaskClub cut Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 12th. Finally, Stephens raised their price objective on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 4th. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $56.50.

Amedisys (AMED) opened at 48.88 on Monday. Amedisys has a one year low of $34.58 and a one year high of $65.91. The company’s 50 day moving average price is $56.08 and its 200-day moving average price is $54.19. The stock has a market capitalization of $1.66 billion, a PE ratio of 41.78 and a beta of 0.89.

In other news, Director Bruce D. Perkins purchased 500 shares of the stock in a transaction on Thursday, May 25th. The stock was bought at an average price of $59.69 per share, with a total value of $29,845.00. Following the transaction, the director now owns 13,331 shares in the company, valued at approximately $795,727.39. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bruce D. Perkins purchased 2,000 shares of the stock in a transaction on Thursday, August 3rd. The shares were purchased at an average cost of $46.60 per share, with a total value of $93,200.00. Following the transaction, the director now owns 15,825 shares in the company, valued at approximately $737,445. The disclosure for this purchase can be found here. Insiders own 2.80% of the company’s stock.

A number of hedge funds have recently modified their holdings of the company. OxFORD Asset Management LLP purchased a new stake in shares of Amedisys during the second quarter worth approximately $2,250,000. Dimensional Fund Advisors LP boosted its stake in shares of Amedisys by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,124,943 shares of the health services provider’s stock worth $70,658,000 after buying an additional 7,963 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of Amedisys by 38.3% in the second quarter. Parametric Portfolio Associates LLC now owns 101,560 shares of the health services provider’s stock worth $6,379,000 after buying an additional 28,133 shares in the last quarter. Suntrust Banks Inc. boosted its stake in shares of Amedisys by 4.3% in the second quarter. Suntrust Banks Inc. now owns 5,702 shares of the health services provider’s stock worth $358,000 after buying an additional 237 shares in the last quarter. Finally, Sawgrass Asset Management LLC purchased a new stake in shares of Amedisys during the second quarter worth approximately $1,048,000. 98.54% of the stock is owned by institutional investors.

WARNING: “$388.54 Million in Sales Expected for Amedisys Inc (NASDAQ:AMED) This Quarter” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/14/388-54-million-in-sales-expected-for-amedisys-inc-nasdaqamed-this-quarter.html.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.